Schering AG and MediGene AG has announced the formation of a world-wide strategic alliance to develop and commercialise MediGene’s Viral Vaccine for the treatment of precancerous lesions of the cervix caused by human papilloma viruses (HPV). Schering has been granted a world-wide exclusive license with the right to grant sublicenses. MediGene has an option for Read more about Schering And MediGene Collaborate On Human Papilloma Virus Treatment[…]